Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Sara Cococcia, Laura Rovedatti, Marco Vincenzo Lenti, Lodovica Pozzi, Federico De Grazia & Antonio Di Sabatino. (2020) Safety and durability of PEG-J: a single-centre experience. Scandinavian Journal of Gastroenterology 55:11, pages 1377-1380.
Read now
Read now
Junaid Siddiqui, Zakiyah Aldaajani, Raja Mehanna, Barbara Kelly Changizi, Danish Bhatti, Ziyad Ghazi Al-Johani, Aparna Wagle Shukla, Hubert H. Fernandez & Jawad A. Bajwa. (2018) Rationale and patient selection for interventional therapies in Parkinson’s disease. Expert Review of Neurotherapeutics 18:11, pages 811-823.
Read now
Read now
Sabine Skodda. (2014) Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease. Journal of Parkinsonism and Restless Legs Syndrome 4, pages 53-62.
Read now
Read now
Johan Lökk, Sara Olofsson & Ulf Persson. (2014) Willingness to pay for a new drug delivery in Parkinson patients. Journal of Multidisciplinary Healthcare 7, pages 431-440.
Read now
Read now
Livia Dézsi & László Vécsei. (2014)
Safinamide for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 23:5, pages 729-742.
Read now
Read now
Wolfgang H Jost. (2014) Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opinion on Drug Safety 13:4, pages 447-458.
Read now
Read now
Adolfo Ramirez-Zamora & Eric Molho. (2014) Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions. Expert Review of Neurotherapeutics 14:1, pages 93-103.
Read now
Read now
J Lökk. (2011) Lack of information and access to advanced treatment for Parkinson’s disease patients. Journal of Multidisciplinary Healthcare 4, pages 433-439.
Read now
Read now
Robert A. Hauser. (2011) Future Treatments for Parkinson's Disease: Surfing the PD Pipeline. International Journal of Neuroscience 121:sup2, pages 53-62.
Read now
Read now
Articles from other publishers (38)
R. Balestrino, T. Martone, M. Toffoli, E. Montanaro, M. Fabbri, C. A. Artusi, A. Romagnolo, M. Zibetti, M. Rizzone, S. Goldwurm, L. Lopiano & A. H. V. Schapira. (2023) Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations. Neurological Sciences.
Crossref
Crossref
Luigi SIVERO, Saverio SICILIANO, Nicola GENNARELLI, Rosa MAIONE, Serena VOLPE, Rosa VITALE, Alessia CHINI & Stefania SIVERO. (2023) Evaluation of a single center on the efficacy of percutaneous endoscopic gastro-jejunostomy (PEG/J) in the therapy of Parkinson's disease with levodopa-carbidopa intestinal gel, from the experimental phase to today. Chirurgia 36:3.
Crossref
Crossref
Germaine Hiu-Fai Chan. (2022) The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson’s Disease: A Mini-Review. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2993
3013
.
R. Balestrino & A.H.V. Schapira. (2019) Parkinson disease. European Journal of Neurology 27:1, pages 27-42.
Crossref
Crossref
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
21
.
Xiao Dong Liu, Yi Bao & Guang jian Liu. (2019) Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology 10.
Crossref
Crossref
Theresa A. Zesiewicz. (2019) Parkinson Disease. CONTINUUM: Lifelong Learning in Neurology 25:4, pages 896-918.
Crossref
Crossref
Tamás Kiss, Tünde Alapi, Gábor Varga, Csilla Bartos, Rita Ambrus, Piroska Szabó-Révész & Gábor Katona. (2019) Interaction Studies Between Levodopa and Different Excipients to Develop Coground Binary Mixtures for Intranasal Application. Journal of Pharmaceutical Sciences 108:8, pages 2552-2560.
Crossref
Crossref
Mujahid Rafiq, Ibrar Hussain, C. M. Nadeem Faisal & Hamid Turab Mirza. 2019. Human Aspects of IT for the Aged Population. Design for the Elderly and Technology Acceptance. Human Aspects of IT for the Aged Population. Design for the Elderly and Technology Acceptance
281
299
.
Thomas Marshall, Amy Pugh, Angelyn Fairchild & Steven Hass. (2017) Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease. Value in Health 20:10, pages 1383-1393.
Crossref
Crossref
Ignacio RegidorVicente BenitaMarta del Álamo de PedroLuis LeyJuan Carlos Martinez Castrillo. (2017) Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation–Refractory Symptoms in Advanced Parkinson Disease. Clinical Neuropharmacology 40:3, pages 103-107.
Crossref
Crossref
L.P. Kotra & J. Park. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
439
473
.
Sarah L. Greig. (2016) Carbidopa/levodopa enteral suspension in advanced Parkinson’s disease: a guide to its use. Drugs & Therapy Perspectives 32:5, pages 177-185.
Crossref
Crossref
Yasaman Kianirad & Tanya Simuni. (2016) Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s Disease. Current Neurology and Neuroscience Reports 16:4.
Crossref
Crossref
Krishe Menezes, Lawrence W. Elmer & Robert A. Hauser. 2016. Parkinson's Disease. Parkinson's Disease
83
92
.
M. Angela Cenci-Nilsson & Per Odin. 2016. Parkinson's Disease. Parkinson's Disease
63
75
.
. 2016. Parkinson's Disease. Parkinson's Disease
1
92
.
Joohi Jimenez-Shahed. (2016) A review of current and novel levodopa formulations for the treatment of Parkinson's disease. Therapeutic Delivery 7:3, pages 179-191.
Crossref
Crossref
Attila Makkos, Endre Pál, Zsuzsanna Aschermann, József Janszky, Éva Balázs, Katalin Takács, Kázmér Karádi, Sámuel Komoly & Norbert Kovács. (2016) High-Frequency Repetitive Transcranial Magnetic Stimulation Can Improve Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Neuropsychobiology 73:3, pages 169-177.
Crossref
Crossref
Maríateresa Buongiorno, Francesca Antonelli, Ana Cámara, Victor Puente, Oriol de Fabregues-Nebot, Jorge Hernandez-Vara, Matilde Calopa, Berta Pascual-Sedano, Antonia Campolongo, Francesc Valldeoriola, Eduardo Tolosa, Jaime Kulisevsky & Maria Jose Martí. (2015) Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism & Related Disorders 21:8, pages 871-876.
Crossref
Crossref
Oluwadamilola O Ojo & Hubert H Fernandez. (2015) Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease. Future Neurology 10:3, pages 191-201.
Crossref
Crossref
Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Maria João Forjaz & Monica M. Kurtis. (2015) Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease. CNS Drugs 29:5, pages 397-413.
Crossref
Crossref
Saeed Bohlega, Hussam Abou Al-Shaar, Thamer Alkhairallah, Fahad Al-Ajlan, Nael Hasan & Khalid Alkahtani. (2015) Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience. European Neurology 74:5-6, pages 227-236.
Crossref
Crossref
F.I. Tarazi, Z.T. Sahli, M. Wolny & S.A. Mousa. (2014) Emerging therapies for Parkinson's disease: From bench to bedside. Pharmacology & Therapeutics 144:2, pages 123-133.
Crossref
Crossref
Fabrizio Stocchi & Paola Stirpe. (2014) The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. Journal of Neural Transmission 121:S1, pages 79-83.
Crossref
Crossref
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra & R. Yañez. (2013) Advanced Parkinson's disease: Clinical characteristics and treatment. Part II. Neurología (English Edition) 28:9, pages 558-583.
Crossref
Crossref
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra & R. Yañez. (2013) Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II. Neurología 28:9, pages 558-583.
Crossref
Crossref
Joseph JankovicCara A Pecina & Alberto J Espay. 2013. Parkinson’s Disease: Medical and Surgical Treatment. Parkinson’s Disease: Medical and Surgical Treatment
43
60
.
Hubert H. Fernandez, Arvydas Vanagunas, Per Odin, Alberto J. Espay, Robert A. Hauser, David G. Standaert, Krai Chatamra, Janet Benesh, Yili Pritchett, Steven L. Hass & Robert A. Lenz. (2013) Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism & Related Disorders 19:3, pages 339-345.
Crossref
Crossref
Wolfgang H. Jost. (2013) Late or early treatment in Parkinson's disease?. Basal Ganglia 3:1, pages 1-3.
Crossref
Crossref
Fernando L. Pagan & Jill Giordano Farmer. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease
466
477
.
Maurizio Zibetti, Aristide Merola, Valeria Ricchi, Alice Marchisio, Carlo Alberto Artusi, Laura Rizzi, Elisa Montanaro, Dario Reggio, Claudio Angelis, Mario Rizzone & Leonardo Lopiano. (2012) Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. Journal of Neurology 260:1, pages 105-114.
Crossref
Crossref
Silvia Sacchi, Laura Caldinelli, Pamela Cappelletti, Loredano Pollegioni & Gianluca Molla. (2012) Structure–function relationships in human d-amino acid oxidase. Amino Acids 43:5, pages 1833-1850.
Crossref
Crossref
D. Nyholm, K. Klangemo & A. Johansson. (2012) Levodopa/carbidopa intestinal gel infusion long‐term therapy in advanced Parkinson’s disease. European Journal of Neurology 19:8, pages 1079-1085.
Crossref
Crossref
Amanda L. Piquet, Kala Venkiteswaran, Neena I. Marupudi, Matthew Berk & Thyagarajan Subramanian. (2012) The immunological challenges of cell transplantation for the treatment of Parkinson's disease. Brain Research Bulletin 88:4, pages 320-331.
Crossref
Crossref
Houman HomayounChristopher G Goetz. (2012) Facing the unique challenges of dyskinesias in Parkinson’s disease. Future Neurology 7:2, pages 127-143.
Crossref
Crossref
Gila Bronner. (2011) Sexual problems in Parkinson's disease: The multidimensional nature of the problem and of the intervention. Journal of the Neurological Sciences 310:1-2, pages 139-143.
Crossref
Crossref